Molecular and biochemical evidence for the presence of type III adenylyl cyclase in human platelets

Platelets

Volumn 14, Issue 1, 2003, Pages 21-33

  Katsel, Pavel L ^a,b   Tagliente, Thomas M ^a   Schwarz, Todd E ^a   Craddock Royal, Barbara D ^a   Patel, Nayana D ^a   Maayani, Saul ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 (TETRAHYDRO 2 FURYL)ADENINE; ADENYLATE CYCLASE; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; COMPLEMENTARY DNA; ENZYME ANTIBODY; ETHYLENEDIAMINE TETRAKIS(METHYLENEPHOSPHONIC ACID); FORSKOLIN; G PROTEIN COUPLED RECEPTOR; ILOPROST; ISOENZYME; ISOPRENALINE; LEPIRUDIN; MAGNESIUM ION; METAL ION; ZINC ION;

ANIMAL TISSUE; ARTICLE; BONE MARROW; CHEMICAL ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME REGULATION; EVIDENCE BASED MEDICINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA; MEGAKARYOCYTE; MOLECULAR BIOLOGY; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PLATELET DEAGGREGATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; WESTERN BLOTTING;

ADENYLATE CYCLASE; BLOOD PLATELETS; BLOTTING, WESTERN; CATIONS, DIVALENT; CELL LINE; GTP-BINDING PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; PLATELET AGGREGATION; RNA, MESSENGER;

ANIMALIA;

EID: 0037327312     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/0953710021000062905     Document Type: Article

References (88)

1. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 222-232.
2. Brass L F, Manning D R, Cichowski K, Abrams C S. Signaling through G proteins in platelets: to the integrins and beyond. Thromb Haemost 1997; 78: 581-589.
3. 1 receptor, necessary but not sufficient to support full ADP- induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol 1998; 103: 858-866.
4. Storey R F, Sanderson H M, White A E, May J A, Cameron K E, Heptinstall S. The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925-934.
5. Steen V M, Holmsen H, Aarbakke G. The platelet-stimulating effect of adrenaline through alpha 2-adrenergic receptors requires simultaneous activation by a true stimulatory platelet agonist. Evidence that adrenaline per se does not induce human platelet activation in vitro. Thromb Haemost 1993; 70: 506-513.
6. Lanza F, Beretz A, Stierle A, Hanau D, Kubina M, Cazenave J P. Epinephrine potentiates human platelet activation but is not an aggregating agent. Am J Physiol 1988; 255: H1276-H1288.
7. Jin J G, Kunapuli S P. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95: 8070-8074.
8. Jantzen H M, Gousset L, Bhaskar V, Vincent D, Tai A, Reynolds E E, et al. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation. Thromb Haemost 1999; 81: 111-117.
9. Maayani S, Schwarz T, Martinez R, Tagliente T M. Activation of Gi-coupled receptors releases a tonic state of inhibited platelet aggregation. Platelets 2001; 12: 94-98.
10. Maayani S, Tagliente T M, Schwarz T, Craddock-Royal B, Alcala C, Marrero G, et al. Deaggregation is an integral component of the response of platelets to ADP in vitro: kinetic studies of literature and original data. Platelets 2001; 12: 279-291.
11. Maayani S, Tagliente T M, Schwarz T, Martinelli G, Martinez R, Shore-Lesserson L. The balance of concurrent aggregation and deaggregation processes in platelets is linked to differential occupancy of ADP receptor subtypes. Platelets 2001; 12: 83-93.
12. Geiger J, Honig-Liedl P, Schanzenbacher P, Walter U. Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors. Eur J Pharmacol 1998; 351: 235-246.
13. Savi P, Labouret C, Delesque N, Guette F, Lupker J, Herbert J M. P2Y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001; 283: 379-383.
14. Salzman E W, Neri L L. Cyclic 3′,5′-adenosine monophosphate in human blood platelets. Nature 1969; 224: 609-610.
15. Salzman E W, Kensler P C, Levine L. Cyclic 3′,5′-adenosine monophosphate in human blood platelets. IV. Regulatory role of cyclic amp in platelet function. Ann N Y Acad Sci 1972; 201: 61-71.
16. Gorman R R, Bunting S, Miller O V. Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 1977; 13: 377-388.
17. Tateson J E, Moncada S, Vane J R. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 1977; 13: 389-397.
18. Schwarz T E, Tagliente T M, Maayani S. Bi-directional modulation of platelet function by adenylyl cyclase IV agents that affect intracellular cAMP levels influence platelet function through acceleration or deceleration of deaggregation in vitro. Blood 2001; 98: 47b.
19. Hurley J H. Structure, mechanism, and regulation of mammalian adenylyl cyclase. J Biol Chem 1999; 274: 7599-7602.
20. Hanoune J, Defer N. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 2001; 41: 145-174.
21. 2+-sensitive adenylyl cyclases. Adv Second Messenger Phosphoprotein Res 1998; 32: 23-51.
22. Newman P J, Gorski J, White G C, Gidwitz S, Cretney C J, Aster R H. Enzymatic amplification of platelet-specific messenger RNA using the polymerase chain reaction. J Clin Invest 1988; 82: 739-743.
23. Roth G J, Hickey M J, Chung D W, Hickstein D D. Circulating human blood platelets retain appreciable amounts of poly (A)+ RNA. Biochem Biophys Res Commun 1989; 160: 705-710.
24. Koesling D, Nurnberg B. Platelet G Proteins and Adenylyl and Guanylyl Cyclases. In: von Bruchhausen F, Walter U, eds. Platelets and Their Factors. Germany: Springer, 1997: 181-218.
25. Katsel P L, Greenstein R J. Differential cholecystokinin brain/gut transcription initiation in the rat: evidence for brain-specific start sites. DNA Cell Biol 1997; 16: 1013-1021.
26. Yang B, He B, Abdel-Halim S M, Tibell A, Brendel M D, Bretzel R G, et al. Molecular cloning of a full-length cDNA for human type 3 adenylyl cyclase and its expression in human islets. Biochem Biophys Res Commun 1999; 254: 548-551.
27. Katsel P L, O'Connell B, Mizuno T M, Mobbs C V, Greenstein R J. Liposome mediated gene transfer into GH3 cells, and rat brain, liver and gut: comparison of different polar and aliphatic domains. Int J Surg Invest 2000; 1: 415-429.
28. Salomon Y, Londos C, Rodbell M. Highly sensitive adenylate cyclase assay. Anal Biochem 1974; 58: 541-548.
29. Bradford M M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
30. Brenner-Gati L, Berg K A, Gershengorn M C. Insulin-like growth factor-I potentiates thyrotropin stimulation of adenylyl cyclase in FRTL-5 cells. Endocrinology 1989; 125: 1315-1320.
31. Gilberts E C A M, Greenstein A J, Katsel P L, Harpaz N, Greenstein R J. Molecular evidence for two forms of Crohn disease. Proc Natl Acad Sci USA 1994; 91: 12721-12724.
32. Bakalyar H A, Reed R R. Identification of a specialized adenylyl cyclase that may mediate odorant detection. Science 1990; 250: 1403-1406.
33. Garbers D L, Johnson R A. Metal and metal-ATP interactions with brain and cardiac adenylate cyclases. J Biol Chem 1975; 250: 8449-8456.
34. Somkuti S G, Hildebrandt J D, Herberg J T, Iyengar R. Divalent cation regulation of adenylyl cyclase. An allosteric site on the catalytic component. J Biol Chem 1982; 257: 6387-6393.
35. Tesmer J J, Sunahara R K, Johnson R A, Gosselin G, Gilman A G, Sprang S R. Two-metal-Ion catalysis in adenylyl cyclase. Science 1999; 285: 756-760.
36. Choi E J, Xia Z, Storm D R. Stimulation of the type III olfactory adenylyl cyclase by calcium and calmodulin. Biochemistry 1992; 31: 6492-6498.
37. Marquis N R, Becker J A, Vigdahl R L. Platelet aggregation. III. An epinephrine induced decrease in cyclic AMP synthesis. Biochem Biophys Res Commun 1970; 39: 783-789.
38. Hollopeter G, Jantzen H M, Vincent D, Li G, England L, Ramakrishnan V, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207.
39. Fabre J -E, Nguyen M, Athirakul K, Coggins K, McNeish J D, Austin S, et al. Activation of the murine EP3 receptor for PGE(2) inhibits cAMP production and promotes platelet aggregation. J Clin Invest 2001; 107: 603-610.
40. Jakobs K H, Saur W, Schultz G. Characterization of alphaand beta-adrenergic receptors linked to human platelet adenylate cyclase. Naunyn Schmiedebergs Arch Pharmacol 1978; 302: 285-291.
41. van Koppen C, Meyer zu Heringdorf M, Laser K T, Zhang C, Jakobs K H, Bunemann M, et al. Activation of a high affinity Gi protein-coupled plasma membrane receptor by sphingosine-1-phosphate. J Biol Chem 1996; 271: 2082-2087.
42. Johnson R A, Shoshani I. Kinetics of "P"-site-mediated inhibition of adenylyl cyclase and the requirements for substrate. J Biol Chem 1990; 265: 11595-11600.
43. Johnson R A, Yeung S M, Stubner D, Bushfield M, Shoshani I. Cation and structural requirements for P site-mediated inhibition of adenylate cyclase. Mol Pharmacol 1989; 35: 681-688.
44. Macphee C H, Harrison S A, Beavo J A. Immunological identification of the major platelet low-Km cAMP phosphodiesterase: probable target for anti-thrombotic agents. Proc Natl Acad Sci U S A 1986; 83: 6660-6663.
45. Graber S E, Hawiger J. Evidence that changes in platelet cyclic AMP levels regulate the fibrinogen receptor on human platelets. J Biol Chem 1982; 257: 14606-14609.
46. Xia Z, Choi E J, Wang F, Storm D R. The type III calcium/calmodulin-sensitive adenylyl cyclase is not specific to olfactory sensory neurons. Neurosci Lett 1992; 144: 169-173.
47. Hellevuo K, Yoshimura M, Kao M, Hoffman P L, Cooper D M, Tabakoff B. A novel adenylyl cyclase sequence cloned from the human erythroleukemia cell line. Biochem Biophys Res Commun 1993; 192: 311-318.
48. Hellevuo K, Welborn R, Menninger J A, Tabakoff B. Human adenylyl cyclase type 7 contains polymorphic repeats in the 3′ untranslated region: investigations of association with alcoholism. Am J Med Genet 1997; 74: 95-98.
49. Rabbani M, Nelson E J, Hoffman P L, Tabakoff B. Role of protein kinase C in ethanol-induced activation of adenylyl cyclase. Alcohol Clin Exp Res 1999; 23: 77-86.
50. Taussig R, Gilman A G. Mammalian membrane-bound adenylyl cyclases. J Biol Chem 1995; 270: 1-4.
51. Albert P R, Sajedi N, Lemonde S, Ghahremani M H. Constitutive G(i2)-dependent activation of adenylyl cyclase type II by the 5-HT1A receptor. Inhibition by anxiolytic partial agonists. J Biol Chem 1999; 274: 35469-35474.
52. Taussig R, Tang W-J, Hepler J R, Gilman A G. Distinct pattern of bidirectional regulation of mammalian adenylyl cyclases. J Biol Chem 1994; 269: 6093-6100.
53. Yoshimura M, Ikeda H, Tabakoff B. mu-Opioid receptors inhibit dopamine-stimulated activity of type V adenylyl cyclase but enhance dopamine-stimulated activity of type VII adenylyl cyclase. Mol Pharmacol 1996; 50: 43-51.
54. Gao B N, Gilman A G. Cloning and expression of a widely distributed (type IV) adenylyl cyclase. Proc Natl Acad Sci U S A 1991; 88: 10178-10182.
55. Haslam R J, Taylor A. Effects of catecholamines on the formation of adenosine 3′:5′-cyclic monophosphate in human blood platelets. Biochem J 1971; 125: 377-379.
56. Matthews J S, Jones R L. Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues. Br J Pharmacol 1993; 108: 363-369.
57. sα-GTPγS. Science 1997; 278: 1907-1916.
58. Pieroni J P, Harry A, Chen J, Jacobowitz O, Magnusson R P, Iyengar R. Distinct characteristics of the basal activities of adenylyl cyclases 2 and 6. J Biol Chem 1995; 270: 21368-21373.
59. Hardy E, Glenn J, Heptinstall S, Rubin P C, Horn E H. Magnesium modifies the responses of platelets to inhibitory agents which act via cAMP. Thromb Haemost 1995; 74: 1132-1137.
60. Ravn H B, Vissinger H, Kristensen S D, Husted S E. Magnesium inhibits platelet activity - an in vitro study. Thromb Haemost 1996; 76: 88-93.
61. Matsuno K, Koyama M, Takeda H, Abe K, Sakurada K, Miyazaki T, et al. Cytosolic free magnesium concentration in human platelets. Thromb Res 1993; 69: 131-137.
62. Yoshimura M, Oshima T, Matsuura H, Watanabe M, Higashi Y, Ono N, et al. Assessment of platelet cytosolic concentration of free magnesium in healthy subjects. J Lab Clin Med 1995; 125: 743-747.
63. Kowalska M A, Juliano D, Trybulec M, Lu W, Niewiarowski S. Zinc ions potentiate adenosine diphosphate-induced platelet aggregation by activation of protein kinase C. J Lab Clin Med 1994; 123: 102-109.
64. Trybulec M, Kowalska M A, McLane M A, Silver L, Lu W, Niewiarowski S. Exposure of platelet fibrinogen receptors by zinc ions: role of protein kinase C. Proc Soc Exp Biol Med 1993; 203: 108-116.
65. Gorodetsky R, Mou X D, Blankenfeld A, Marx G. Platelet Multielemental Composition, Lability, and Subcellular-Localization. Am J Hematol 1993; 42: 278-283.
66. 2+ inside platelet secretory granules. Measurements employing a novel double null point technique. J Biol Chem 1983; 258: 14774-14777.
67. 2A receptors. J Biol Chem 1999; 274: 29108-29114.
68. Haslam R J, Davidson M M, Desjardins J V. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP. Biochem J 1978; 176: 83-95.
69. Savi P, Pflieger A M, Herbert J M. cAMP is not an important messenger for ADP-induced platelet aggregation. Blood Coagul Fibrinolysis 1996; 7: 249-252.
70. Daniel J L, Dangelmaier C, Jin J, Kim Y B, Kunapuli S P. Role of intracellular signaling events in ADP-induced platelet aggregation. Thromb Haemost 1999; 82: 1322-1326.
71. Dangelmaier C, Jin J, Smith J B, Kunapuli S P. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway. Thromb Haemost 2001; 85: 341-348.
72. Florio V A, Ross E M. Regulation of the catalytic component of adenylate cyclase. Potentiative interaction of stimulatory ligands and 2′,5′-dideoxyadenosine. Mol Pharmacol 1983; 24: 195-202.
73. 1 and adenosine on metal and metal-ATP kinetics of platelet adenylate cyclase. J Biol Chem 1979; 254: 1094-1101.
74. Dessauer C W, Gilman A G. The catalytic mechanism of mammalian adenylyl cyclase. Equilibrium binding and kinetic analysis of P-site inhibition. J Biol Chem 1997; 272: 27787-27795.
75. Guinebault C, Payrastre B, Racaud-Sultan C, Mazarguil H, Breton M, Mauco G, et al. Integrin-dependent translocation of phosphoinositide 3-kinase to the cytoskeleton of thrombin-activated platelets involves specific interactions of p85 alpha with actin filaments and focal adhesion kinase. J Cell Biol 1995; 129: 831-842.
76. Maier U, Babich A, Nurnberg B. Roles of non-catalytic subunits in betagamma-induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma. J Biol Chem 1999; 274: 29311-29317.
77. Zhang J, Benovic J L, Sugai M, Wetzker R, Gout I, Rittenhouse S E. Sequestration of a G-protein beta gamma subunit or ADP-ribosylation of Rho can inhibit thrombin-induced activation of platelet phosphoinositide 3-kinases. J Biol Chem 1995; 270: 6589-6594.
78. 3 integrin. J Biol Chem 1996; 271: 6265-6272.
79. Kim S, Jee K, Kim D, Koh H, Chung J. Cyclic AMP inhibits Akt activity by blocking the membrane localization of PDK1. J Biol Chem 2001; 276: 12864-12870.
80. 2A-adrenoceptor mediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro. Platelets 2001; 12: 359-375.
81. Villacres E C, Xia Z, Bookbinder L H, Edelhoff S, Disteche C M, Storm D R. Cloning, chromosomal mapping, and expression of human fetal brain type I adenylyl cyclase. Genomics 1993; 16: 473-478.
82. Stengel D, Parma J, Gannage M H, Roeckel N, Mattei M G, Barouki R, et al. Different chromosomal localization of two adenylyl cyclase genes expressed in human brain. Hum Genet 1992; 90: 126-130.
83. Parma J, Stengel D, Gannage M H, Poyard M, Barouki R, Hanoune J. Sequence of a human brain adenylyl cyclase partial cDNA: evidence for a consensus cyclase specific domain. Biochem Biophys Res Commun 1991; 179: 455-462.
84. Krupinski J, Lehman T C, Frankenfield C D, Zwaagstra J C, Watson P A. Molecular diversity in the adenylylcyclase family. Evidence for eight forms of the enzyme and cloning of type VI. J Biol Chem 1992; 267: 24858-24862.
85. Volkel H, Beitz E, Klumpp S, Schultz J E. Cloning and expression of a bovine adenylyl cyclase type VII specific to the retinal pigment epithelium. FEBS Lett 1996; 378: 245-249.
86. 2+/calmodulin-stimulated enzyme expressed in discrete regions of rat brain. J Biol Chem 1994; 269: 12190-12195.
87. Hacker B M, Tomlinson J E, Wayman G A, Sultana R, Chan G, Villacres E, et al. Cloning, chromosomal mapping, and regulatory properties of the human type 9 adenylyl cyclase (ADCY9). Genomics 1998; 50: 97-104.
88. Buck J, Sinclair M L, Schapal L, Cann M J, Levin L R. Cytosolic adenylyl cyclase defines a unique signaling molecule in mammals. Proc Natl Acad Sci U S A 1999; 96: 79-84.